Vaxart Slides After Reporting Delay Of Trial For Potential COVID-19 Oral Vaccine

person holding black round plate

Image Source: Unsplash

Shares of Vaxart (VXRT) are under pressure on Monday after the company reported worse-than-expected first quarter losses and said that its Phase II trial of VXA-CoV2-1 is now expected to start mid-year 2021 instead of in the second quarter.

Vaxart is expected to provide new data comparing the T-Cell responses induced by its VXA-CoV2-1 vaccine with those of other vaccines and present new mucosal antibody data and review the recent Phase 1 clinical results that suggest VXA-CoV2-1 is potentially protective against new and future COVID-19 strains due to the vaccine’s more conserved target.

Results

Vaxart reported first quarter losses per share of 14 cents and revenue of $506,000, both below the expected 10 cents and $620,000, respectively. Vaxart ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3 million, compared to $126.9 million as of Dec. 31, 2020.

Trial Delay

Alongside quarterly results, Vaxart said that its Phase II trial of VXA-CoV2-1, the company's vaccine encoding both the S and the N proteins, is now expected to start mid-year 2021 instead of in the second quarter. The delay is due to manufacturing issues at the Baltimore contract manufacturing facility, the same facility where other COVID-19 vaccine manufacturers have also reported issues, the company said.

New Data

Vaxart is expected to provide new data comparing the T-cell responses induced by its VXA-CoV2-1 vaccine with those of other vaccines.

"The recent results of a poll we commissioned suggested that as many as 19 million more Americans would decide to get vaccinated against COVID-19 if the vaccine was administered as a pill instead of a needle injection — a number we expect to be much higher worldwide, particularly given the distribution advantages of a room-temperature stable tablet. That alone could potentially make a significant global impact,” said Andrei Floroiu, Chief Executive Officer of Vaxart.

1 2
View single page >> |

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Angry Old Lady 1 week ago Member's comment

"Alongside quarterly results, Vaxart said that its Phase II trial of VXA-CoV2-1, the company's vaccine encoding both the S and the N proteins, is now expected to start mid-year 2021 instead of in the second quarter. The delay is due to manufacturing issues at the Baltimore contract manufacturing facility, the same facility where other COVID-19 vaccine manufacturers have also reported issues, the company said."

We will be in the mid-year 2021 in June..